Total synthesis of a biotinylated rocaglate: Selective targeting of the translation factors eIF4AI/II
Graphical abstract
Section snippets
Acknowledgments
We thank the Australian Research Council-Discovery Grants Scheme for funding. LML holds an NHMRC Peter Doherty Early Career Fellowship (1035502). Research on this subject is supported by the Victorian State Government Operational Infrastructure Support and Australian Government NHMRC IRIISS to WEHI (LML).
References and notes (21)
- Meurer-Grimes, B. M.; Yu, J.; Vario, G. L. WO 2002002566, A1 20020110, 2004,...
- et al.
J. Org. Chem.
(2004) - et al.
J. Am. Chem. Soc
(2004)et al.J. Am. Chem. Soc.
(2006) - et al.
Org. Biomol. Chem.
(2010) - (1992)
- et al.
Prog. Chem. Org. Nat. Prod.
(2011)et al.Nat. Prod. Rep.
(2014)et al.Prog. Chem. Org. Nat. Prod.
(2011) - et al.
J. Chem. Soc., Chem. Commun.
(1982) - et al.
Eur. J. Pharmacol.
(1992) - et al.
Phytochemistry
(1993) - et al.
Angew. Chem., Int. Ed.
(2007)et al.J. Am. Chem. Soc.
(2009)et al.Angew. Chem., Int. Ed.
(2007)et al.J. Nat. Prod.
(2012)
Cited by (7)
Dual targeting of DDX3 and eIF4A by the translation inhibitor rocaglamide A
2021, Cell Chemical BiologyCitation Excerpt :This was probably due to the complicated nature of the action of RocA and the target proteins. A biochemical approach with biotinylated RocA and subsequent purification in a mammalian system (Chambers et al., 2013, 2016) was not performed with polypurine RNA during purification, as we did in this study (Figure 2A). Given that RocA binds in the bimolecular cavity between polypurine RNA and the targeted DEAD-box protein (Iwasaki et al., 2019), the ability to capture the full target proteins may be limited.
The Translation Inhibitor Rocaglamide Targets a Bimolecular Cavity between eIF4A and Polypurine RNA
2019, Molecular CellCitation Excerpt :Whereas Phe163Leu-Ile199Met mutations clearly rendered human eIF4A1 resistant to RocA in vitro (Figure 5), their in vivo effects were still modest (Figure 4). This difference was probably caused by the presence of a highly homologous eIF4A1 paralog, eIF4A2, which has been also reported as a target of rocaglates (Chambers et al., 2013, 2016). Although its expression is relatively low compared to eIF4A1 in the HEK293 cells used in this study (Figure S5F), the potent dominant-negative effect of RocA (Iwasaki et al., 2016) could be induced via the minor paralog of eIF4A.
Halogenated Rocaglate Derivatives: Pan-antiviral Agents against Hepatitis E Virus and Emerging Viruses
2024, Journal of Medicinal ChemistryThe Synthesis and Biological Evaluation of Some C-9 and C-10 Substituted Derivatives of the RNA Polymerase i Transcription Inhibitor CX-5461
2021, Australian Journal of Chemistry